Denali Therapeutics Inc. DNLI Increase (Decrease) In Non-Cash Operating Lease Expense
Increase (Decrease) In Non-Cash Operating Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept dnli:IncreaseDecreaseInNonCashOperatingLeaseExpense.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s increase (decrease) in non-cash operating lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s increase (decrease) in non-cash operating lease expense?
- Denali Therapeutics Inc. (DNLI) reported increase (decrease) in non-cash operating lease expense of $1.14M in Q1 2026.
- How has Denali Therapeutics Inc.'s increase (decrease) in non-cash operating lease expense changed year-over-year?
- Denali Therapeutics Inc.'s increase (decrease) in non-cash operating lease expense increased by 9.1% year-over-year, from $1.05M to $1.14M.
- What is the long-term trend for Denali Therapeutics Inc.'s increase (decrease) in non-cash operating lease expense?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s increase (decrease) in non-cash operating lease expense has grown at a 10.5% compound annual growth rate (CAGR), from $2.98M to $4.45M.
- What does increase (decrease) in non-cash operating lease expense mean?
- This metric captures the non-cash impact of operating lease expenses on the statement of cash flows, typically representing the difference between the recognized lease expense and the actual cash payments made. It adjusts net income to reflect the accounting treatment of lease obligations under current standards. Monitoring this helps analysts understand the extent to which operating expenses are driven by non-cash lease accounting rather than cash outflows.